ERRα represents a promising metabolic vulnerability in prostate cancer and PCSCs, and targeting mitochondrial metabolism in PCSCs through inhibition of ERRα provides a novel paradigm for developing more effective therapeutic strategies for advanced prostate cancer. The gene discussed is ESRRA; the disease is Familial prostate cancer.